NASTECH PHARMACEUTICAL IS LOSING GROUND ON FDA

Nastech Pharmaceutical announced Thursday morning that it received written notification from the FDA, on July 10, that the company's abbreviated new drug application for intranasal calcitonin-salmon is not approvable at this time. Trading Markets (http://www.tradingmarkets.com/tm.site/news/STOCK%20ALERT/304352/)